VenusP-Valve Pivotal Study (PROTEUS STUDY)

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

August 30, 2034

Conditions
Pulmonary Regurgitation
Interventions
DEVICE

Transcatheter pulmonary valve implantation (TPVI)

A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.

DEVICE

VenusP-ValveTM System

"VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."

Trial Locations (1)

92618

RECRUITING

Venusmedtech of America, Irvine

All Listed Sponsors
lead

Venus MedTech (HangZhou) Inc.

INDUSTRY